Akpa’s systems pharmacology models help set ATOM apart from other AI-driven drug discovery methods. She will leverage ORNL’s high-performance computing capabilities, such as the Summit supercomputer, in her quest to get drugs to patients faster with a greater probability of success.

“Tackling a virus requires a multipronged approach in the big-picture way of not only having an arsenal to respond with as the virus changes over time, but also recognizing that trying to kill something that’s not really alive is a very hard task,” says Marti Head of Oak Ridge National Laboratory (ORNL), who leads the molecular design project of the National Virtual Biotechnology Laboratory (NVBL).

After announcing the launch of the COVID-19 High Performance Computing Consortium on Sunday, the Department of Energy yesterday provided more details on its scope and operation in a briefing led by Undersecretary of Energy Paul Dabbar and attended by HPC leaders from national labs. The joint public-private effort will pool 16 systems which together offer…

Lawrence Livermore National Laboratory scientists are contributing to the global fight against COVID-19 by combining artificial intelligence/machine learning, bioinformatics and supercomputing to help discover….

Drug discovery has always been a slow and laborious process by nature, with researchers finding dead ends much more frequently than successful routes to the clinic...

At the world’s pharma and biotech companies, artificial intelligence is increasingly critical to the drug discovery engine…

Argonne has announced its commitment to become the newest member of ATOM, a public-private partnership between national laboratories, academic institutions and private industry…